Form 4: Syros Pharmaceuticals Director Richard A. Young Sells Shares
SEC Form 4 Filing
Director Richard A. Young sold 34,837 shares of Syros Pharmaceuticals (SYRS) at $5.12 per share on June 28, 2024, according to a Form 4 filing.
Summary
- Richard A. Young, a director of Syros Pharmaceuticals, sold 34,837 shares of common stock on June 28, 2024.
- The sale price was $5.12 per share.
- Following the transaction, Young directly owns 8,000 shares of Syros Pharmaceuticals.
- The sale was executed under a pre-arranged trading plan adopted on March 29, 2024, in accordance with Rule 10b5-1.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports a routine transaction under a pre-arranged trading plan. It doesn't inherently indicate positive or negative prospects for the company.
Industry Context
Insider sales are common and can be for various reasons, including diversification or personal financial planning. The use of a 10b5-1 plan suggests the sale was pre-planned and not based on current inside information.
Stakeholder Impact
- The sale of shares by a director could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 03/29/2024 | Date of adoption of the Rule 10b5-1 trading plan. |
| 06/28/2024 | Date of the stock sale transaction. |
| 07/02/2024 | Date of the Form 4 filing. |
Keywords
Form 4, Syros Pharmaceuticals, SYRS, Richard A. Young, stock sale, insider trading, Rule 10b5-1, director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.